Multiple paradigm shifts in multiple sclerosis.

Area of Science:

• Neuroimmunology
• Neurology
• Pathogenesis of Multiple Sclerosis

Background:

• Multiple sclerosis (MS) pathogenesis understanding has evolved, shifting focus from demyelination to axonal loss as the primary driver of permanent disability.
• Current therapeutic strategies for MS are under continuous scientific debate, necessitating a review of available treatments and emerging concepts.

Discussion:

• Axonal loss dictates permanent clinical disability in MS, yet methods to prevent this damage are still elusive.
• While remyelination is theoretically possible, its failure within MS lesions requires further investigation.
• The role of inflammation in MS is complex, with evidence suggesting potential benefits alongside its detrimental effects.

Key Insights:

• Early initiation of treatment with immunomodulatory drugs is critical for managing MS progression.
• Immunosuppressive strategies show efficacy in progressive forms of MS, particularly when other disease-modifying drugs are ineffective.
• Mitoxantrone is a viable option for progressive MS cases unresponsive to other therapies.

Outlook:

• Further research into the interaction between myelinating cells and neurons may yield novel treatment concepts for MS.
• Optimizing the use of current approved therapies remains paramount while awaiting new treatment breakthroughs.
• Ongoing trials emphasize the need for timely intervention with immunomodulatory treatments in MS management.